Whats the near-term environment for systems biology companies?
We don’t see many companies doing what we do. There’s a smattering of companies out there doing in silico types of things associated more with data mining and qualitative linking. So you have a company like Ingenuity [Systems] that’s using more of a data-mining technique to identify qualitative links to things. There are a ton of companies doing that, and they’re going to have some moderate success. I don’t think they’re like us … Are Entelos’ models quantitative? Are you building models that drill down to predict cellular mRNA concentrations? Basically our models, since they’re top-down, are more intercellular than intracellular, so we’re looking at cell-to-cell communication. Yes, we’re looking at quantitative changes, so we’re saying that this is a kinetic between biology A and biology B, and this is the dose-response curve associated with this toxicity. Lots of people have qualitative pathway maps hanging on their walls. That’s a long way from actually manipulating something and
